Evaluating the One-Year Efficacy of Combined Anti-VEGF and Dexamethasone Implant Treatment for Macular Edema in Retinal Vein Occlusions

11 June 2023 : Clinical Research

Fengmei Ren^B, Hui Gong^D, Han Zhang^D, Xiaoguang Zhang^E, Xiaolin Liu^F, Peifeng Gao^D, Junying Li^G, Guisen Zhang

^AE

DOI: 10.12659/MSM.939277

Med Sci Monit 2023; 29:e939277

Background Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 2 Characteristics of all included subjects by subgroup.

	CRVO (n=17)	BRVO (n=17)	P
Age	56.00±6.33	54.24±6.29	0.558
Male (%)/female (%)	8 (47.1)/9 (52.9)	7 (41.2)/10 (58.8)	0.730
Medical history			0.789
With diabetes (%)	7 (4.1)	7 (4.1)
With hypertension (%)	1 (5.9)	2 (11.8)
Type			0.271
With ischemia (%)	4 (23.5)	7 (41.2)
Without ischemia (%)	13 (76.5)	10 (58.5)
Number of injections (n)	3.29±1.11	3.00±0.94	0.408
Baseline BCVA (LogMar)	0.29±0.24	0.32±0.20	0.726
Baseline IOP (mmHg)	16.24±2.33	15.82±3.03	0.660
Baseline CRT (μm)	662.82±191.23	637.24±174.13	0.686
Baseline SCP	45.91±5.10	44.77±4.87	0.507
Baseline DCP	44.52±4.92	44.52±4.12	0.997
FAZ area (mm)	0.36±0.29	0.28±0.11	0.264
FAZ circumference (mm)	2.31±0.82	2.03±0.61	0.266
FAZ – foveal avascular zone; CRT – central retinal thickness; SCP – superficial capillary plexus; DCP – deep capillary plexus; IOP – intraocular pressure; BCVA – best corrected visual acuity.

Back to the Article